Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Retained Earnings: 2015-2025

Historic Retained Earnings for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to -$2.5 billion.

  • Intellia Therapeutics' Retained Earnings fell 21.76% to -$2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 billion, marking a year-over-year decrease of 21.76%. This contributed to the annual value of -$2.2 billion for FY2024, which is 31.30% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Retained Earnings of -$2.5 billion as of Q3 2025, which was down 4.23% from -$2.4 billion recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Retained Earnings peaked at -$481.3 million during Q1 2021, and registered a low of -$2.5 billion during Q3 2025.
  • Its 3-year average for Retained Earnings is -$1.9 billion, with a median of -$1.9 billion in 2024.
  • Data for Intellia Therapeutics' Retained Earnings shows a maximum YoY crashed of 76.57% (in 2022) over the last 5 years.
  • Intellia Therapeutics' Retained Earnings (Quarterly) stood at -$703.0 million in 2021, then crashed by 67.45% to -$1.2 billion in 2022, then plummeted by 40.88% to -$1.7 billion in 2023, then tumbled by 31.30% to -$2.2 billion in 2024, then dropped by 21.76% to -$2.5 billion in 2025.
  • Its last three reported values are -$2.5 billion in Q3 2025, -$2.4 billion for Q2 2025, and -$2.3 billion during Q1 2025.